Morphabond ER - (15,30,60,100 mg; Tablet, Extended Release)

Generic Name	Morphine Sulfate	Innovator	Daiichi Sankyo
Dosage	15,30,60,100 mg; Tablet, Extended Release	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MORPHABOND ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****	*** \ *********	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events